Compare · NBP vs NVO
NBP vs NVO
Side-by-side comparison of NovaBridge Biosciences (NBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 1084.9x NBP ($205.4M).
- Over the past year, NBP is down 16.4% and NVO is down 22.5% - NBP leads by 6.1 points.
- NBP has been more active in the news (9 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for NBP).
- Company
- NovaBridge Biosciences
- Novo Nordisk A/S
- Price
- $1.78-0.56%
- $50.31-2.25%
- Market cap
- $205.4M
- $222.81B
- 1M return
- +17.88%
- +15.47%
- 1Y return
- -16.43%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 9
- 4
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NBP
- SEC Form 6-K filed by NovaBridge Biosciences
- SEC Form 4 filed by Chief Commercial Officer Hagler Mark Arnold
- SEC Form 4 filed by General Counsel Lin Liwei Lorraine
- SEC Form 4 filed by Chief Executive Officer Gupta Srishti
- SEC Form 3 filed by new insider Gupta Srishti
- SVP, Clinical Development Xu Cong Claire converted options into 12,432 units of Ordinary Shares and sold $3,992 worth of Ordinary Shares (4,485 units at $0.89), increasing direct ownership by 3% to 298,101 units (SEC Form 4)
- SEC Form 4 filed by Director Fu Wei
- SEC Form 6-K filed by NovaBridge Biosciences
- NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
- SEC Form 4 filed by Chief Bus. Development Officer Cao Sean Wuxiong
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S